{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"125","value":"334"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"467"}],"units":"Participants"}],"description":"Cmax was measured for all participants that received at least one dose of Atezolizumab.","dispersionType":"Standard Deviation","groups":[{"description":"Atezolizumab was administered intravenously at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Participants received atezolizumab as long as they continued to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.","id":"OG000","title":"Atezolizumab"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK-evaluable population is defined as patients who received atezolizumab treatment and had at least one measureable PK concentration.","reportingStatus":"POSTED","timeFrame":"30 minutes post dose on Day 1 of Cycles 1","title":"Maximum Observed Serum Atezolizumab Concentration (Cmax)","type":"SECONDARY","unitOfMeasure":"mcg/mL"}